In principle, identifying appropriate oncogenic signaling pathways that regulate gliomagenesis, through transcriptional regulation of HSPB1, is appealing for developing a therapeutic approach to selectively-target therapy-resistant GBM cells. The gene discussed is HSPB1; the disease is glioblastoma.